97 related articles for article (PubMed ID: 1814852)
1. The combined treatment of human peripheral blood mononuclear cells with thymolymphotropin and interleukin 2 increases PPD-driven T-cell proliferation and IL-2 induced cellular cytotoxicity against HIV-infected cells.
Di Massimo AM; Gilardini Montani MS; Bardone MR; Moras ML; Malkovsky M; Antonelli G; Colizzi V
Int J Immunopharmacol; 1991; 13(8):1157-65. PubMed ID: 1814852
[TBL] [Abstract][Full Text] [Related]
2. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
[TBL] [Abstract][Full Text] [Related]
4. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells.
Oshimi K; Oshimi Y; Saito H; Mizoguchi H
J Immunol Methods; 1988 May; 109(2):161-8. PubMed ID: 3258896
[TBL] [Abstract][Full Text] [Related]
6. In vivo activated lymphoid cells (IVALC) affect the cloning efficiency of human T lymphocytes reactive to a soluble antigen, purified protein derivative.
Sia DY; Chou JL
Scand J Immunol; 1987 Dec; 26(6):683-90. PubMed ID: 3122312
[TBL] [Abstract][Full Text] [Related]
7. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
8. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
9. In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients.
Lucey DR; Pinto LA; Bethke FR; Rusnak J; Melcher GP; Hashemi FN; Landay AL; Kessler HA; Paxton RJ; Grabstein K; Shearer GM
Clin Diagn Lab Immunol; 1997 Jan; 4(1):43-8. PubMed ID: 9008279
[TBL] [Abstract][Full Text] [Related]
10. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
11. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells.
Gosselin J; Menezes J; Mercier G; Lamoureux G; Oth D
Viral Immunol; 1990; 3(1):55-65. PubMed ID: 2153385
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
14. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
15. Proliferation of functional human natural killer cells with anti-HIV-1 activity in NOD/SCID/Jak3(null) mice.
Hattori S; Matsuda K; Kariya R; Harada H; Okada S
Microbiol Immunol; 2016 Feb; 60(2):106-13. PubMed ID: 26708420
[TBL] [Abstract][Full Text] [Related]
16. Impact of IL-2 and IL-2R SNPs on proliferation and tumor- killing activity of lymphokine-activated killer cells from healthy chinese blood donors.
Li Y; Meng FD; Tian X; Sui CG; Liu YP; Jiang YH
Asian Pac J Cancer Prev; 2014; 15(18):7965-70. PubMed ID: 25292096
[TBL] [Abstract][Full Text] [Related]
17. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines.
Goletti D; Weissman D; Jackson RW; Collins F; Kinter A; Fauci AS
J Infect Dis; 1998 May; 177(5):1332-8. PubMed ID: 9593021
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection.
Teppler H; Kaplan G; Smith K; Cameron P; Montana A; Meyn P; Cohn Z
J Infect Dis; 1993 Feb; 167(2):291-8. PubMed ID: 8421163
[TBL] [Abstract][Full Text] [Related]
19. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.
Yanagisawa M; Kato M; Ikeno K; Kobayashi T; Miyagawa Y; Komiyama A; Akabane T
Clin Exp Immunol; 1987 May; 68(2):251-8. PubMed ID: 2820633
[TBL] [Abstract][Full Text] [Related]
20. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
